Radiopharmaceuticals Market Research Report with Forecast 2026 to 2035
Segmentation of Radiopharmaceuticals Market-
Radiopharmaceuticals Market - By Radioisotope
- Technetium 99
- Fluorine 18
- Iodine 131
- Leutetium 177
- Yttrium 90
- Gallium 67
- Gallium 68
- Rubidium 82
- Iodine 123
- Iodine 125
- Indium 111
- Other Isotopes
Radiopharmaceuticals Market – By Source
- Cyclotrons
- Nuclear Reactors
- Other Sources
Radiopharmaceuticals Market – By Type
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
Radiopharmaceuticals -By Technology / Modality
- SPECT Radiopharmaceuticals
- PET Radiopharmaceuticals
- Beta-emitting Radiopharmaceuticals
- Alpha-emitting Radiopharmaceuticals
Radiopharmaceuticals -By Indication
- Oncology
- Cardiology
- Gastroenterology
- Neuroendocrinology
- Neurology
- Nephrology
- Other Indications
Radiopharmaceuticals- By End User
- Hospitals
- Medical Imaging Centers
- Cancer Research Institutes
Radiopharmaceuticals Market – By End User
- Hospitals
- Medical Imaging Centers
- Cancer Research Institute
Radiopharmaceuticals Market By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceuticals Market Snapshot
Chapter 4. Global Radiopharmaceuticals Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Radioisotope Estimates & Trend Analysis
5.1. By Radioisotope, & Market Share, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Radioisotope:
5.2.1. Technetium 99
5.2.2. Fluorine 18
5.2.3. Iodine 131
5.2.4. Leutetium 177
5.2.5. Yttrium 90
5.2.6. Gallium 67
5.2.7. Gallium 68
5.2.8. Rubidium 82
5.2.9. Iodine 123
5.2.10. Iodine 125
5.2.11. Indium 111
5.2.12. Other Isotopes
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Indication:
6.2.1. Oncology
6.2.2. Cardiology
6.2.3. Gastoenterology
6.2.4. Neuroendocrinology
6.2.5. Neurology
6.2.6. Nephrology
6.2.7. Other Indications
Chapter 7. Market Segmentation 3: By Source Estimates & Trend Analysis
7.1. By Source & Market Share, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Source:
7.2.1. Cyclotrons
7.2.2. Nuclear Reactors
7.2.3. Other Sources
Chapter 8. Market Segmentation 4: By Type Estimates & Trend Analysis
8.1. By Type & Market Share, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By Type:
8.2.1. Diagnostic Radiopharmaceuticals
8.2.2. Therapeutic Radiopharmaceuticals
Chapter 9. Market Segmentation 5: By End-Users Estimates & Trend Analysis
9.1. By End-Users & Market Share, 2025 & 2035
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following By End-Users:
9.2.1. Hospitals
9.2.2. Medical Imaging Centers
9.2.3. Cancer Research Institute
9.2.4. Other End Users
Chapter 10. Market Segmentation 6: By Technology / Modality Estimates & Trend Analysis
10.1. By Technology / Modality & Market Share, 2025 & 2035
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Technology / Modality:
10.2.1. SPECT Radiopharmaceuticals
10.2.2. PET Radiopharmaceuticals
10.2.3. Beta-emitting Radiopharmaceuticals
10.2.4. Alpha-emitting Radiopharmaceuticals
Chapter 11. Radiopharmaceuticals Market Segmentation 6: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2022 - 2035
11.1.2. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Indication, 2022 - 2035
11.1.3. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Source, 2022 - 2035
11.1.4. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Type, 2022 - 2035
11.1.5. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By End-Users, 2022 - 2035
11.1.6. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Technology / Modality, 2022 - 2035
11.1.7. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By country, 2022 - 2035
11.2. Europe
11.2.1. Europe Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, 2022 - 2035
11.2.2. Europe Radiopharmaceuticals Market revenue (US$ Million) By Indication, 2022 - 2035
11.2.3. Europe Radiopharmaceuticals Market revenue (US$ Million) By Source, 2022 - 2035
11.2.4. Europe Radiopharmaceuticals Market revenue (US$ Million) By Type, 2022 - 2035
11.2.5. Europe Radiopharmaceuticals Market revenue (US$ Million) By End-Users, 2022 - 2035
11.2.6. Europe Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.2.7. Europe Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
11.3. Asia Pacific
11.3.1. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, 2022 - 2035
11.3.2. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Indication, 2022 - 2035
11.3.3. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Source, 2022 - 2035
11.3.4. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Type, 2022 - 2035
11.3.5. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By End-Users, 2022 - 2035
11.3.6. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.3.7. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
11.4. Latin America
11.4.1. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, (US$ Million) 2022 - 2035
11.4.2. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Indication, (US$ Million) 2022 - 2035
11.4.3. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Source, (US$ Million) 2022 - 2035
11.4.4. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Type, (US$ Million) 2022 - 2035
11.4.5. Latin America Radiopharmaceuticals Market revenue (US$ Million) By End-Users, (US$ Million) 2022 - 2035
11.4.6. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.4.7. Latin America Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
11.5. Middle East & Africa
11.5.1. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, (US$ Million) 2022 - 2035
11.5.2. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Indication, (US$ Million) 2022 - 2035
11.5.3. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Source, (US$ Million) 2022 - 2035
11.5.4. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Type, (US$ Million) 2022 - 2035
11.5.5. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By End-Users, (US$ Million) 2022 - 2035
11.5.6. Middle East a& Africa Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2022 - 2035
11.5.7. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) by country, 2022 - 2035
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Novartis AG
12.2.2. Curium SAS
12.2.3. Bayer AG
12.2.4. Telix Pharmaceuticals Limited
12.2.5. Lantheus Holdings, Inc.
12.2.6. GE HealthCare Technologies Inc.
12.2.7. Cardinal Health, Inc.
12.2.8. Jubilant Pharmova Limited
12.2.9. ITM Isotope Technologies Munich SE
12.2.10. Eli Lilly and Company
12.2.11. AstraZeneca PLC
12.2.12. PharmaLogic Holdings Corp.
12.2.13. Life Molecular Imaging GmbH
12.2.14. Bracco Imaging S.p.A.
12.2.15. Siemens Healthineers AG
12.2.16. Eckert & Ziegler Strahlen- und Medizintechnik AG
12.2.17. NorthStar Medical Radioisotopes, LLC
12.2.18. Nusano, Inc.
12.2.19. Nordion (Canada) Inc.
12.2.20. IBA RadioPharma Solutions (Ion Beam Applications S.A.)
12.2.21. ANSTO
12.2.22. Yantai Dongcheng Pharmaceutical Group Co., Ltd.
12.2.23. Others
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Radiopharmaceuticals Market Size is valued at USD 6.73 Bn in 2025 and is predicted to reach USD 22.88 Bn by the year 2035.
Radiopharmaceuticals Market is expected to grow at a 13.4% CAGR during the forecast period for 2026-2035.
Novartis AG, Curium SAS, Bayer AG, Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., GE HealthCare Technologies Inc., Cardinal Health, Inc., Jubilant Pharmova Limited, ITM Isotope Technologies Munich SE, Eli Lilly and Company, AstraZeneca PLC, PharmaLogic Holdings Corp., Life Molecular Imaging GmbH, Bracco Imaging S.p.A., Siemens Healthineers AG, Eckert & Ziegler Strahlen- und Medizintechnik AG, NorthStar Medical Radioisotopes, LLC, Nusano, Inc., Nordion (Canada) Inc., IBA RadioPharma Solutions (Ion Beam Applications S.A.), ANSTO, Yantai Dongcheng Pharmaceutical Group Co., Ltd. and Others
Radiopharmaceuticals Market is segmented based on radioisotope, technology type, indication, source, type, and end user, Radioisotope, the market is segmented into technetium 99, fluorine 18, iodine 131, leutetium 177, yttrium 90, gallium 67, gallium 68, rubidium 82, iodine 123, iodine 125, indium 111, other isotopes.
North American region is leading the Radiopharmaceuticals Market.